Benzinga | Aug 2, 2021 11:11AM EDT

Hoth Therapeutics Starts Preclinical Study For Its Alzheimer's Candidate

* Hoth Therapeutics Inc (NASDAQ:HOTH) has initiated its preclinical study utilizing Hoth's HT-ALZ in an animal model.

* The study aims to determine the effects of HT-ALZ on behavioral and pathological markers of Alzheimer's disease and determine if HT-ALZ can improve learning and memory in an animal model of Alzheimer's disease.

* Hoth study will also determine if the behavior is improved utilizing HT-ALZ in blocking NK-1Rs.

* The designed studies are taking place under a Scientific Research Agreement entered by Hoth in June 2021.

* Price Action: HOTH shares are up 3.87% at $1.34 during the market session on the last check Monday.